A phase 2b, randomised, double-blind, active controlled, multi centre study to evaluate the efficacy, safety and tolerability of oral AZD9977 and dapagliflozin treatment in patients with heart failure
A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure